Ketazolam

from Wikipedia, the free encyclopedia
Structural formula
Structural formula of ketazolam
General
Surname Ketazolam
other names

11-chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl-4 H - (1,3) -oxazino [ 3,2- d ] [1,4] -benzodiazepine-4,7 (6 H ) -dione

Molecular formula C 20 H 17 ClN 2 O 3
External identifiers / databases
CAS number 27223-35-4
EC number 248-346-3
ECHA InfoCard 100.043.937
PubChem 33746
ChemSpider 31110
DrugBank DB01587
Wikidata Q2397253
Drug information
ATC code

N05 BA10

properties
Molar mass 368.818 g mol −1
safety instructions
Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS hazard labeling
no classification available
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Ketazolam is a chemical compound from the benzodiazepine group of active ingredients , but structurally it is one of the diazepams .

Extraction and presentation

Ketazolam can be obtained by reacting diazepam with acetyl chloride in the presence of triethylamine , which was first carried out in 1970 by Szmuszkovisz.

properties

Ketazolam is an oxazinobenzodiazepane. It is a prodrug and is converted relatively quickly into the active metabolites ( desmethylketazolam , then nordiazepam ) after oral administration of absorption , which can accumulate due to their long half-lives. Diazepam and temazepam only occur as minor metabolites. Since the maximum plasma level is only reached with a certain delay, the connection to acute therapy and as a hypnotic is less suitable.

use

Ketazolam is used as an anti-anxiety drug. The average daily dose as an anxiolytic is 15 to 60 mg.

proof

Ketazolam can only be detected poorly by GLC due to the conversion to diazepam. Detection by HPLC is better.

Legal status

In Germany, ketazolam is subject to the Narcotics Act . Here it is listed in Appendix III (marketable and prescription narcotics).

Individual evidence

  1. This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
  2. Julio Alvarez-Builla, Juan José Vaquero, José Barluenga: Modern Heterocyclic Chemistry Vol. 1 . John Wiley & Sons, 2011, ISBN 978-3-527-33201-4 , pp. 2415 ( limited preview in Google Book search).
  3. Andre Rosowsky: azepine . John Wiley & Sons, 2009, ISBN 0-470-18874-X , pp. 876 ( limited preview in Google Book search).
  4. ^ A b G. Langer, H. Heimann: Psychopharmaka Basics and Therapy . Springer-Verlag, 2013, ISBN 978-3-7091-7645-0 , p. 339 ( limited preview in Google Book search).
  5. ^ Karl-Heinz Beyer: Biotransformation der Arzneimittel . Springer-Verlag, 2013, ISBN 978-3-642-74386-3 , pp. 312 ( limited preview in Google Book search).
  6. ^ A b Otto Benkert, Hanns Hippius: Psychiatrische Pharmakotherapie . Springer-Verlag, 2013, ISBN 978-3-642-97350-5 , p. 280 ( limited preview in Google Book search).
  7. ^ S. Pryde, MT Gilbert: Applications of High Performance Liquid Chromatography . Springer Science & Business Media, 1979, ISBN 978-0-412-14220-8 , pp. 82 ( limited preview in Google Book search).